newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//U.S. News & World Report
The two-drug combination of doravirine and islatravir was approved to replace the current antiretroviral regimen.
The FDA approved Merck's once-daily oral combination regimen for certain adults with HIV-1.
KEY POINTS
The newly approved regimen combines doravirine with experimental drug islatravir.
This regimen is intended to replace current antiretroviral treatments for eligible HIV-1 patients.
Doravirine is currently marketed as Pifeltro and Delstrigo, but islatravir was experimental before this approval.
April 21 (Reuters) - The U.S. Food and Drug Administration has approved Merck's once-daily, oral, combination regimen for HIV infections, the health regulator's website showed on Tuesday.
The two-drug combination of doravirine and islatravir was approved to replace the current antiretroviral regimen for treating HIV-1 infection in some adults.
While islatravir is an experimental treatment, Merck's doravirine is already approved and sold in the U.S. under brand name Pifeltro for HIV-1 treatment in combination with other antiretrovirals, and as a single-tablet regimen, Delstrigo.
About 40.8 million people are living with HIV globally, with about 1.3 million new infections occurring annually, according to National Institutes of Health data.
The drugmaker did not immediately respond to Reuters requests for comment.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Sahal Muhammed and Shinjini Ganguli)